G P Hadley1, M Mars, P K Ramdial. 1. Department of Paediatric Surgery, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. hadley@ukzn.ac.za
Abstract
PURPOSE: To present our experience of 20 children with bilateral Wilms' tumour seen in a resource-challenged environment over a 10-year period. METHOD: All patients with a diagnosis of bilateral synchronous Wilms' tumour were identified and recruited. RESULTS: Study patients represented 11 % of a cohort of 177 new patients with Wilms' tumour seen over the same period. Three patients had a syndromic predisposition to Wilms' tumour. Metastatic disease was seen at presentation in four patients (20 %) and three children presented with unilateral tumour rupture. One patient presented with paraplegia and one with obstruction of the duodenum. All children received neoadjuvant chemotherapy. One HIV-infected child died of IRIS after neoadjuvant treatment, but before surgery. One child died of progressive disease after unilateral nephrectomy. Nephron-sparing surgery was performed in 22 kidneys and 15 kidneys were removed in toto. Following enucleation of tumours, three children had positive margins. Discordant histopathology was seen in 53 % of patients. Overall survival at 2 years is 85 %. CONCLUSION: Despite significant co-morbidity and advanced disease, bilateral Wilms' tumour is a treatable disease in a resource-constrained environment.
PURPOSE: To present our experience of 20 children with bilateral Wilms' tumour seen in a resource-challenged environment over a 10-year period. METHOD: All patients with a diagnosis of bilateral synchronous Wilms' tumour were identified and recruited. RESULTS: Study patients represented 11 % of a cohort of 177 new patients with Wilms' tumour seen over the same period. Three patients had a syndromic predisposition to Wilms' tumour. Metastatic disease was seen at presentation in four patients (20 %) and three children presented with unilateral tumour rupture. One patient presented with paraplegia and one with obstruction of the duodenum. All children received neoadjuvant chemotherapy. One HIV-infectedchild died of IRIS after neoadjuvant treatment, but before surgery. One child died of progressive disease after unilateral nephrectomy. Nephron-sparing surgery was performed in 22 kidneys and 15 kidneys were removed in toto. Following enucleation of tumours, three children had positive margins. Discordant histopathology was seen in 53 % of patients. Overall survival at 2 years is 85 %. CONCLUSION: Despite significant co-morbidity and advanced disease, bilateral Wilms' tumour is a treatable disease in a resource-constrained environment.
Authors: Alastair J W Millar; Alan Davidson; Heinz Rode; Alp Numanoglu; Patricia S Hartley; John D Daubenton; Farieda Desai Journal: J Pediatr Surg Date: 2005-08 Impact factor: 2.545
Authors: Robert C Shamberger; Gerald M Haase; Pedram Argani; Elizabeth J Perlman; Cecilia A Cotton; Janice Takashima; Daniel M Green; Michael L Ritchey Journal: J Pediatr Surg Date: 2006-04 Impact factor: 2.545
Authors: Daniel C Aronson; Annelie Slaar; Richard C Heinen; Jan de Kraker; Hugo A Heij Journal: Pediatr Blood Cancer Date: 2011-03-02 Impact factor: 3.167
Authors: J R Horwitz; M L Ritchey; J Moksness; N E Breslow; G R Smith; P R Thomas; G Haase; R C Shamberger; J B Beckwith Journal: J Pediatr Surg Date: 1996-08 Impact factor: 2.545
Authors: A C Paulino; J Wilimas; N Marina; D Jones; M Kumar; C Greenwald; G Chen; L E Kun Journal: Int J Radiat Oncol Biol Phys Date: 1996-10-01 Impact factor: 7.038
Authors: Andrew M Davidoff; Dana W Giel; Deborah P Jones; Jesse J Jenkins; Matthew J Krasin; Fredric A Hoffer; Mark A Williams; Jeffrey S Dome Journal: Cancer Date: 2008-05-01 Impact factor: 6.860
Authors: Sophie E van Peer; Janna A Hol; Alida F W van der Steeg; Martine van Grotel; Godelieve A M Tytgat; Annelies M C Mavinkurve-Groothuis; Geert O R Janssens; Annemieke S Littooij; Ronald R de Krijger; Marjolijn C J Jongmans; Marc R Lilien; Jarno Drost; Roland P Kuiper; Harm van Tinteren; Marc H W A Wijnen; Marry M van den Heuvel-Eibrink Journal: J Clin Med Date: 2021-11-26 Impact factor: 4.241